Article Text

Download PDFPDF
Mycophenolate mofetil treatment in children and adolescents with lupus
  1. Ina Kazyra1,
  2. Clarissa Pilkington2,
  3. Stephen D Marks3,
  4. Kjell Tullus3
  1. 1Department of Paediatrics, Belarus State Medical University, Minsk, Belarus
  2. 2Department of Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, UK
  3. 3Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK
  1. Correspondence to Kjell Tullus, Department of Paediatric Nephrology, Nephrology Unit, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK; tulluk{at}


Safety and efficacy data are presented on the use of mycophenolate mofetil (MMF) in 26 children and adolescents with lupus. Data include therapy before and 12 months after starting MMF. 18 of 26 patients had biopsy-proved lupus nephritis. Group 1 were commenced on MMF induction and/or maintenance therapy (n=14), group 2 converted from azathioprine because of inadequate disease control (n=12). 73% of all (10 (71%) group 1 and 10 (83%) group 2) patients experienced a significant improvement in British Isles Lupus Assessment Group score (from median 9.0 to 3.0). Children with hypocomplementaemia increased their C3 significantly in both groups (0.53–1.15 for group 1 and 0.63–1.2 g/l for group 2, p=0.001), and C4 level only in group 1 (0.08–0.17, p=0.01). Renal function and albuminuria improved in those with active nephritis (p≤0.01). Significant improvements were seen in both groups in haemoglobin, erythrocyte sedimentation rate and lymphocyte counts. Prednisolone dose was weaned in both groups, p<0.05. Side-effects were seen in four patients, but none was judged to be severe enough to discontinue treatment. MMF treatment in this cohort of children with lupus seemed to be safe, well tolerated and effective.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.